SA.60012(2020/X) The project concerns the implementation of an innovative technology for the production of Onko BCG for bladder cancer immunotherapy based on the Moreau attenuated BCG tuberculosis in a vial under vacuum. The implementation will be carried out on the basis of the R & D works carried out by the Applicant. The implementation of the results of R & D works, which will enable the offer of product manufacturing services based on innovative technology, will take place in three stages: 1. construction of a dedicated production building 2.organisation of dedicated and complete production infrastructure, 3. qualification of infrastructure and validation of the manufacturing process Validation will confirm the correctness of the implemented technology by meeting the requirements and quality characteristics of the medicinal product specified in the specifications, in accordance with the provisions of Rozp. Health regarding GMP requirements and will enable the start of the production process. The innovativeness of the process is due to the specificity of the strain used, which is characterised by high safety. At present, no other technologies are known and used in the treatment of bladder cancer based on the Moreau subvaccination of BCG tuberculosis. Only the Applicant’s technology is known (currently used, showing a fairly high level of defects, based on closing the drug in the form of an ampoule submerged in the flame of the burner). Other technologies are used on the scale of the entire market, but none of them has so far been verified and dedicated to the Moreau substrain. The company is the sole owner of the implemented know-how. The project is also part of the National Oncological Strategy. Taking into account the market analysis, the report on the results of R & D works, the results of the analysis of the current state of technology and the technological processes used in the industry, it should be considered that this project demonstrates innovation on a scale that exceeds the scale of the country and will be included in the scope of the priority investments of the Company.